Prelude Therapeutics Inc·4

Oct 20, 4:16 PM ET

Dorton Katina 4

4 · Prelude Therapeutics Inc · Filed Oct 20, 2025

Insider Transaction Report

Form 4
Period: 2025-10-17
Transactions
  • Award

    Director Stock Option (Right to Buy)

    2025-10-17+76,00076,000 total
    Exercise: $1.19Exp: 2035-10-16Common Stock (76,000 underlying)
Footnotes (1)
  • [F1]The option award vests over a three year period equally one-thirty-sixth per month, subject to Reporting Person's continued service to the Company on each vesting date.

Documents

2 files